ESMIT Live Webinar series
Easily accessible from the comfort of your own home – Get the best of ESMIT education without travelling!
Live webinars are condensed pieces of live, high-quality education which include theoretical presentations, case-based teachings, and a lot of interaction between our facilitators and our participants.
Through this series of live webinars, experts in the field of nuclear medicine will share their knowledge about various topics in an interactive online setting accessible from all over the world.
- All webinars are written and facilitated in English.
- The webinars have an average duration of 60 minutes.
- After the live event has taken place, the recording will be accessible on our eLearning platform. You can access the eLearning materials by logging in with your personal username and password or easily creating a new confidential account.
- Participants of the live webinar series will receive CME credits if the webinar is accredited.
Upcoming ESMIT Live Webinars in 2022
Save the dates!
We are looking forward to seeing you at the ESMIT Live Webinars in 2022:
| 10.02.2022 | The VISION Trial: What we Have to Get Ready for | Theranostics |
| 18.02.2022 | Getting Ready for Total Body PET | Scientific Track |
| 04.03.2022 | The Secrets of Theranostic Practice | Theranostics |
| 18.03.2022 | Spotlight on FOCUS Meeting 2022 | Clinical Nuc. Med. |
| 08.04.2022 | Next in the Pipeline of Theranostics | Theranostics |
| 06.05.2022 | Spotlight on Tumour Microenvironment: What Is Next in Imaging Phenotyping? | Scientific Track |
| 20.05.2022 | Burning Issues of Radioprotection in a Theranostic Unit | Theranostics |
| 03.06.2022 | Make MRI the Best Friend for Amyloid PET | Clinical Nuc. Med. |
| 16.09.2022 | Alpha-Emitters: Still a Game for Scientists or Ready for the Clinical Arena? | Theranostics |
| 18.11.2022 | Maximising Personalised Approaches through Imaging Biomarkers | AI & Quantification |
| 02.12.2022 | Technical Drawbacks in Hybrid Imaging: Understanding the Pitfalls | Technologists |
Webinars will be held at 1:30 pm CEST and have a duration of 60 minutes.
Click here to register for the ESMIT Live Webinars through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
03.06.2022 – Make MRI the Best Friend for Amyloid PET
June 3, 2022 – 13:30 CEST
| Speakers & Moderators: |
 Henryk Barthel |
Karl-Titus Hoffmann |
| Target Audience: | Nuclear Medicine/Radiology In Training and Specialist Physicians | |
Content:
This webinar will provide an update on what information is derived by MRI in patients with (suspected) dementia disorders, and on how MRI – either acquired before or in parallel to the PET scan – can help to improve the amyloid pathology diagnosis.
Learning Objectives:
MRI is the first-line imaging technology in subjects with suspected dementia disorders. As such, the MRI finding should always be considered when interpreting amyloid PET scans. The aim of this webinar is to provide an update on what information is derived by MRI in patients with (suspected) dementia disorders, and on how MRI – either acquired before or in parallel to the PET scan – can help to improve the amyloid pathology diagnosis.
Faculty:
Henryk Barthel
Karl-Titus Hoffmann
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
16.09.2022 – Alpha-Emitters: Still a Game for Scientists or Ready for the Clinical Arena?
September 16, 2022 – 13:30 CEST
| Speakers: | Tim van den Wyngaert | Karolien Goffin | Leszek Krolicki |
| Moderator: | Mike Sathekge | ||
| Target Audience: | Nuclear Medicine/Radiology/Radiation Oncologists In Training and Specialist Physicians, Radiopharmacists, Physicists | ||
Content:
This webinar will provide an in-depth overview of the use of alpha-emitters for radionuclide therapy with a special focus on their clinical application in bone metastasis, prostate cancer and glioma. The advantages and critical aspects of their application as well as issues related to their supply and safety profile will be discussed to provide insight to advance the field towards establishing clinical impact.
Learning Objectives:
After this webinar participants will
- Understand the clinical needs for the implantation of RLT with alpha emitters.
- Learn about the status of the art of RLT with alpha emitters in bone metastasis palliation, prostate cancer and glioma.
- Understand the toxicity profile of RLT with alpha emitters.
- Learn differences in the radiobiology of alpha emitters as compared to beta emitters.
- Learn about the future development of the field.
Faculty:
Tim van den Wyngaert
Karolien Goffin
Mike Sathekge
Leszek Krolicki
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
18.11.2022 – Maximising Personalised Approaches through Imaging Biomarkers
November 18, 2022 – 13:30 CET
| Speakers: | Dimitris Visvikis | Mathieu Hatt | Margarita Kirienko |
| Moderator: | Martina Sollini | ||
| Target Audience: | Physicians, medical physicists, technologists | ||
Content:
Patient stratification, treatment personalisation and response monitoring are key applications of multimodality imaging. The current clinical practice involves the integration of simple image semi-quantitative measures, representing global tumour characteristics and hence cannot capture the complete spectrum of information that can be extracted from acquired multimodality images. The hypothesis can be made that characterising tumour anatomical and functional heterogeneity in a global, regional, and/or local fashion using imaging biomarkers (radiomics) may be related to underlying tumour phenotype and associated heterogeneity. Although starting earlier in the field of anatomical imaging, the field of radiomics has over the last decade witnessed enormous growth in multimodality PET/CT/MR imaging. Finally, the recent introduction of artificial intelligence for the construction of predictive and prognostic models using imaging biomarkers will be discussed as well as remaining challenges for their introduction in routine clinical practice.
Learning Objectives:
After this webinar participants will
- Understanding of the basics of radiomics.
- Role of artificial intelligence in multiparametric modelling using imaging biomarkers.
- Most promising clinical applications.
- Challenges for their routine clinical implementation.
Faculty:
Dimitris Visvikis
Mathieu Hatt
Margarita Kirienko
Martina Sollini
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
02.12.2022 – Technical Drawbacks in Hybrid Imaging: Understanding the Pitfalls
December 2, 2022 – 13:30 CET
| Speakers: | Markus Lonsdale | tbc |
| Moderators: | Rie Strand Olsen | |
| Target Audience: | Nuclear Medicine Technologists | |
Content:
This webinar is focused on information sharing in artefacts and pitfalls in nuclear medicine; SPECT/CT, PET/CT and PET/MR providing an overview of which errors can occur during those scans and how we can prevent and correct them.
Learning Objectives:
After this webinar participants will
- Know about the following topics: Artefacts and pitfalls in SPECT/CT, PET/CT and PET/MR
Faculty:
Rie Strand Olsen
Markus Lonsdale
TBC
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
Past ESMIT 2022 Live Webinars
10.02.2022 – The VISION Trial: What we Have to Get Ready for
February 10, 2022 – 13:30 CET
| Speakers: |
 Ken Herrmann |
 Bernd Krause |
| Moderator: |
 Paola Anna Erba |
|
| Target Audience: | The target audience includes Nuclear Medicine specialists, Physicists as well as (Radiation) Oncologists and Urologists. | |
Content:
This webinar is focused on the advanced management of prostate cancer with emphasis on the role of PSMA radioligands in the treatment of metastatic disease. Through the analysis of the design and the results of the VISION trial, the attendees will learn the definitions, aims, methodology, results and side-effects of 177Lu-PSMA treatment. Criteria for patients’ selection for such treatment will be also discussed. Furthermore, challenges for the future of nuclear medicine practice related to the approval of the 177Lu-PSMA agents will be presented.
Learning Objectives:
After this webinar participants will know about
- Design and results of the VISION trial
- Treatment of metastatic prostate cancer
- Procedure for the election of patients for 177Lu-PSMA treatment
- 177Lu-PSMA treatment side effects
- Future challenges of PSMA-radioligand treatment
Faculty:
Bernd Krause: Head of Department, University Medical Centre, Department of Nuclear Medicine – Rostock, Germany
Ken Herrmann: Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen and as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA – Essen, Germany
Paola Anna Erba: EANM Education Chair and Associate Professor, University of Pisa Medical School – Pisa, Italy
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
This first Live Webinar of the year will be freely accessible. Please fill out this form to sign up and save yourself a seat. You will be enrolled to the ESMIT eLearning platform and will receive further information on how to access the webinar via email.
18.02.2022 – Getting Ready for Total Body PET
February 18, 2022 – 13:30 CET
| Speakers: |
 Stefaan Vandenberghe |
 Riemer Slart |
| Moderators: |
Paola Anna Erba |
 Stephan Nekolla |
| Target Audience: | The target audience includes Nuclear Medicine specialists and researchers, Physicists, Chemists/Radiochemists/Radiopharmacists. | |
Content:
This webinar is focused on the long axial field of view (LAFOV), providing an overview of the camera system implementation and optimisation from the original idea to the currently available clinical systems. Opportunities and challenges in the clinical application of the equipment and the scientific expectations for advancing diagnosis, therapy evaluation and research will be discussed, including the advantages and the current limitations of the available systems as well as basic challenges, especially when capitalising on the full power of LAFOV PET systems for deriving reliable kinetic information. Further, the challenges for the optimal management of such complex scanners will also be addressed.
Learning Objectives:
After this webinar participants will know about
- Design and technical implementation of LAFOV PET/CT
- Roadmap for optimisation
- Challenges in the clinical implementation
- Benefits of LAFOV PET over standard systems
- Current clinical application of LAFOV
- Value for research
- Challenges in LAFOV data analysis and quantitation
Faculty:
Stefaan Vandenberghe: Research Professor, Ghent University – Ghent, Belgium
Riemer Slart: University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging – Groningen, Netherlands
Paola Anna Erba: EANM Education Chair and Associate Professor, University of Pisa Medical School – Pisa, Italy
Stephan Nekolla: Director Medical Physics, Adjunct Teaching Professor, Klinikum rechts der Isar der Technischen Universität München – Munich, Germany
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
This Live Webinar will be freely accessible. Please fill out this form to sign up and save yourself a seat. You will be enrolled to the ESMIT eLearning platform in a few days and will receive further information on how to access the webinar via email.
04.03.2022 – The Secrets of Theranostic Practice
March 4, 2022 – 13:30 CET
| Speakers: |
 Lisa Bodei |
 Andrei Gafita |
 Sona Balogova |
| Moderators: |
 Gopinath Gnanasegaran |
Ken Herrmann |
|
| Target Audience: |
Nuclear Medicine Physicians, Oncologists, Physicists, Technologists, Nurses, |
||
Content:
The faculty will systematically share their experience and discuss the current evidence, trends, success, and challenges related to nuclear medicine theranostic application. Webinars related to neuroendocrine tumours, prostate cancer, and breast cancers will be presented by Nuclear Medicine Physicians from the US and Europe. The faculty will participate in a panel discussion enlightening on integrating these into current and future clinical paradigms.
Learning Objectives:
After this webinar participants will
- Understand the principle, science, and practice of Theranostic in neuroendocrine tumours, prostate cancer and breast cancer.
- Know about current evidence and trends related to theranostic approaches in managing these tumours.
- Know about the management of common technical & clinical challenges in the implementation and delivery of theranostic service.
Faculty:
Lisa Bodei: Director, Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Centre – New York, USA
Andrei Gafita: Post-doctoral Fellow Ahmanson Translational Theranostic Division of the Department of Molecular and Medical Pharmacology at UCLA – Los Angeles, USA
Sona Balogova: Department of Nuclear Medicine of Comenius University and St Elisabeth
Oncology Institute, Bratislava, Slovakia and Department of Nuclear Medicine, Hôpital Tenon AP-HP and Sorbonne, Université, Paris, France – Bratislava, Slovakia
Gopinath Gnanasegaran: Consultant Physician in Nuclear Medicine, Royal Free London NHS Foundation Trust – London, UK
Ken Herrmann: Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen and as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA – Essen, Germany
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
This Live Webinar will be freely accessible. Please fill out this form to sign up and save yourself a seat. You will be enrolled to the ESMIT eLearning platform in a few days and will receive further information on how to access the webinar via email.
18.03.2022 – Spotlight on FOCUS Meeting 2022
March 18, 2022 – 13:30 CET
| Speakers: |
 Jolanta Kunikowska |
 Cristina Nanni |
 Carsten Kobe |
| Moderator: |
Ken Herrmann |
||
| Target Audience: | Board certified Nuclear Medicine physicians, Nuclear Medicine residents, Internal Medicine residents, final year medical students. | ||
Content:
This webinar will provide an in-depth overview and critical assessment of the latest development and future directions in the management of haematological tumours, with a focus on the role of molecular imaging in general and nuclear medicine in particular. The multidisciplinary consensus, achieved among FOCUS4 panellists, on the current state of the art and to make expert recommendations on how to advance the field towards establishing clinical impact will be summarised and translated to the audience.
Learning Objectives:
After this webinar participants will
- Understand when PET is and should be used in NHL, Hodgkin lymphoma and Myeloma.
- Learn about the potential radionuclide therapies in haematological tumours.
- Discover new tools and modalities for the diagnosis and therapy of haematological tumours.
Faculty:
Jolanta Kunikowska: EANM President and Associate Professor, Department of Nuclear Medicine, Medical University of Warsaw – Warsaw, Poland
Cristina Nanni: Nuclear Medicine, IRCCS AOU S. Orsola-Malpighi – Bologna, Italy
Carsten Kobe: Department for Nuclear Medicine, University Hospital of Cologne – Cologne, Germany
Ken Herrmann: Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen and as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA – Essen, Germany
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
08.04.2022 – Next in the Pipeline of Theranostics
April 8, 2022 – 13:30 CEST
| Speakers: |
 Jacopo Millul |
 Bart Cornelissen |
| Moderator: | Christophe Deroose | |
| Target Audience: | Board certified Nuclear Medicine Physicians/Oncologists, Nuclear Medicine residents, Internal Medicine residents, final year medical students, Radiochemists, Radiopharmacists, Researchers. | |
Content:
In recent years there has been a great expansion in the application of theranostics, beginning with [68Ga/177Lu]-labelled somatostatin peptides for neuroendocrine tumours. We are currently seeing the rapid development of [68Ga/177Lu]PSMA theranostics in metastatic prostate cancer. In this webinar we will provide an insight on the most relevant and promising novel theranostic agents in the pipeline.
Learning Objectives:
After this webinar participants will
- Learn how imaging can significantly contribute to the selection of the best therapeutic strategy.
- Understand the possible strategies to use imaging as guide to therapy (not limited to RLT).
- Learn about the current status and future development of cancer cell targets agents for imaging and therapy.
- Learn about the current status and future development of TME agents for imaging and therapy, including cellular and stromal targets.
- Learn about the most promising theranostics agents ready to enter the clinical arena.
Faculty:
Jacopo Millul: Postdoc at University Hospital Basel – Basel, Switzerland
Bart Cornelissen: Senior researcher at the University Medical Center Groningen and honorary Associate Professor at the University of Oxford – Oxford, UK
Christophe Deroose
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
06.05.2022 – Spotlight on Tumour Microenvironment: What Is Next in Imaging Phenotyping?
May 6, 2022 – 13:30 CEST
| Speakers: |
 Margret Schottelius |
 Philipp Backhaus |
Paola Anna Erba |
| Moderator: |
 Luigi Aloj |
||
| Target Audience: | Board-certified Nuclear Medicine Physicians/Oncologists, Nuclear Medicine residents, Internal Medicine residents, final year medical students, Radiochemists, Radiopharmacists, Researchers | ||
Content:
The tumour microenvironment is a complex, heterogeneous, and dominant component of solid tumours. In this webinar we will provide an overview of imaging strategies of a subset of characteristics of the tumour microenvironment, providing potential biomarkers of cancer onset and progression. Further, we will review the current knowledge of intratumoral phenotypic heterogeneity a feature providing disease progression and dismal outcomes, beyond the tumour cell metabolism.
Learning Objectives:
After this webinar participants will
- Understand the meaning and the clinical needs for imaging phenotyping of disease, in particular cancer.
- Learn about the current research on the field.
- Learn about the role of imaging in the field of multi-omics disease characterisation.
- Understand the clinical value of quantitative measurement of human disease.
- Learn about the possibilities of targets and pathways discoveries characterising disease subsets.
- Understand the diagnostic and prognostic meaning of imaging derived parameters.
- Learn about the significant challenges in terms of re-designing the culture of patient care and scientific research this approach requires.
Faculty:
Paola Anna Erba: EANM Education Chair and Associate Professor, University of Pisa Medical School – Pisa, Italy
Margret Schottelius: Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine and Molecular Imaging, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) – Lausanne, Switzerland
Philipp Backhaus: Fellow in Nuclear Oncology, MIT Service, Dept. of Radiology, Memorial Sloan Kettering Cancer Center, NYC, USA; Postdoc at European Institute for Molecular Imaging (EIMI), Münster, Germany; Clinician scientist at Department of Nuclear Medicine, University Hospital Münster (UKM) – Münster, Germany
Luigi Aloj: Consultant Nuclear Medicine Physician, Department of Radiology, University of Cambridge School of Clinical Medicine – Cambridge, UK
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.
20.05.2022 – Burning Issues of Radioprotection in a Theranostic Unit
May 20, 2022 – 13:30 CEST
| Speakers: |
 Jens Kurth |
 Arturo Chiti |
| Moderators: |
 Giovanni Tosi |
 Sigrid Leide Svegborn |
| Target Audience: | Physicists, Physicians, Technologists, Nurses | |
Content:
Personalised medicine is widely discussed, but only intermittently implemented. The use of theranostics by whole-body molecular imaging modalities allows assessment of druggable target expression as well as target accessibility of all lesions, defining patient populations that most likely benefit from radioligand therapy with their therapeutic counterparts. Molecular imaging-based theranostics exclude patients from being exposed to a priori futile therapy. In a world of limited resources and an ever-growing number of treatment options, it remains crucial to select the optimal treatment for each individual patient. The ability to efficiently exclude patients through the use of theranostics is important to ensure effective treatment, from both a patient perspective and a health care perspective, but also emphasises the need for additional parameters and the development of more sophisticated algorithms to allow for optimal patient selection, rather than using a one-size-fits-all concept.
Learning Objectives:
The aim of this course will be to highlight how to set up a theranostic unit from the radioprotection point of view.
Faculty:
Jens Kurth: Medical physicist – Universitätsmedizin Rostock Klinik und Poliklinik für Nuklearmedizin Germany – Rostock, Germany
Arturo Chiti: Department of Biomedical Sciences, Humanitas University, IRCCS Humanitas Research Hospital – Milan, Italy
Giovanni Tosi: Medical physicist, Humanitas Research Hospital – Rozzano Italy
Sigrid Leide Svegborn: Associate Prof., Department of Radiation Physics, Skåne University Hospital, Malmö, and Medical radiation physics, Department of translational medicine, Lund University, Sweden – Malmö, Sweden
CME Credits:
This Event has been accredited with 1 European CME credit (ECMEC), assigned by the EACCME.
Available Tickets:
Click here to register for this webinar through the brand new ESMIT registration tool connecting your eLearning account directly to your myEANM account! Just log into Brightspace and click on ‘Register now!’
You can also access the course store by logging into your myEANM account, clicking on “eLearning platform” in the left sidebar menu and then choosing “Register Now!” in the horizontal navigation.